Gyre Therapeutics (GYRE) Free Cash Flow Growth (1y) (2011 - 2026)
Gyre Therapeutics (GYRE) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
88.70% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-15.72% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
66.37% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Gyre Therapeutics |
554.75 Mn |
540.62 Mn |
8.38 Mn |
1,303.98% |
| Date | Value |
|---|
| Mar 31, 2026 |
1,303.98% |
| Dec 31, 2025 |
-113.29% |
| Sep 30, 2025 |
280.64% |
| Jun 30, 2025 |
126.95% |
| Mar 31, 2025 |
-109.46% |
| Dec 31, 2024 |
-359.94% |
| Sep 30, 2024 |
-81.58% |
| Jun 30, 2024 |
-437.99% |
| Mar 31, 2024 |
-69.42% |
| Dec 31, 2023 |
-97.55% |
| Sep 30, 2023 |
177.06% |
| Jun 30, 2023 |
116.72% |
| Mar 31, 2023 |
171.99% |
| Dec 31, 2022 |
339.30% |
| Sep 30, 2022 |
67.06% |
| Jun 30, 2022 |
38.91% |
| Mar 31, 2022 |
50.53% |
| Dec 31, 2021 |
20.07% |
| Sep 30, 2021 |
-67.33% |
| Jun 30, 2021 |
-32.81% |
